2022 Q2 Financial Report

By Microbix Admin | November 11, 2022

High-Risk HPV Quality Controls are Needed to Uphold Clinical Laboratory Quality Standards

By Microbix Admin | November 10, 2022

Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab© for use as cross-platform compatible EQA samples and laboratory Quality Control

By Microbix Admin | November 10, 2022

Emerging requirements for infectious disease IVD quality control material

By Microbix Admin | November 10, 2022

Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Controls

By Microbix Admin | November 10, 2022

Expected stability of REDx&#8482FLOQ © SARS-CoV-2 Swab Positive Control and REDx&#8482FLOQ© SARS-CoV-2 Swab Negative Control in various sample transport media and storage conditions

By Microbix Admin | November 9, 2022

2022 Q3 Financial Report

By Microbix Admin | November 9, 2022

Use of REDx™FLOQ © SARS-CoV-2 Ag Swab Positive Control and REDx™FLOQ© Respiratory Swab Negative Control as Quality Control by POC devices in various testing conditions

By Microbix Admin | November 8, 2022

Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods

By Microbix Admin | November 8, 2022

Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel

By Microbix Admin | November 7, 2022

Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory Quality Control

By Microbix Admin | November 6, 2022

Novel Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control

By Microbix Admin | November 6, 2022

Simulated swab specimens for whole workflow quality control of SARS-CoV-2 molecular diagnostic testing

By Microbix Admin | November 5, 2022

2022 Q1 Financial Report

By Microbix Admin | November 5, 2022

Episode 3: Diagnostics: Beyond the lab – Self-Collection with Copan Italia

By Microbix Admin | November 5, 2022

Advanced SARS-CoV-2 Variants of Concern (VOC) whole-genome materials for use as verification, external quality assessment (EQA) and prospective quality control samples

By Microbix Admin | November 4, 2022

Episode 2: Diagnostics: Beyond the Lab – AMR MGEN with Colin Denver from SpeeDx

By Microbix Admin | November 4, 2022

Advanced SARS-CoV-2 nucleocapsid protein swab-based formulation for use as a cross-platform EQA sample and as a prospective Quality Control

By Microbix Admin | November 3, 2022

Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective quality controls

By Microbix Admin | November 2, 2022

Novel SARS-CoV-2 Full-Genome Material for Use in a Swab-Based Formulation as a Multi-Platform NAAT Quality Control

By Microbix Admin | November 1, 2022

Episode 1: Diagnostics: Beyond the lab – HPV with Larry Vaughn, BD and Dr. Cathy Popadiuk

By Microbix Admin | November 1, 2022

MBX Investor Update Webinar

By Microbix Admin | October 31, 2022

AGM Presentation – March 2022

By Microbix Admin | October 31, 2022

AGM PRESENTATION 2022

By Microbix Admin | October 31, 2022

Microbix Corporate Presentation – September 2022

By Microbix Admin | October 31, 2022

Microbix Corporate Presentation – October 2022

By Microbix Admin | October 31, 2022

Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods

By Microbix Admin | October 24, 2022

Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Controls

By Microbix Admin | October 24, 2022

Emerging requirements for infectious disease IVD quality control material

By Microbix Admin | October 18, 2022

CEM Muskoka – September 23-25

By Microbix Admin | July 25, 2022

CEM Florida – November 11-13

By Microbix Admin | July 25, 2022

2022 AMMI Canada-CACMID Annual Conference – April 5-8

By Microbix Admin | March 3, 2022

2022 EUROGIN International Multidisciplinary HPV Congress – April 10-13

By Microbix Admin | March 3, 2022

Why We Need To Test COVID-19 Tests

By Microbix Admin | March 3, 2021

Microbix Discloses New Products, Sales, And Capacity

By Microbix Admin | October 29, 2020 Microbix Discloses New Products, Sales, And Capacity

Microbix Creates Further COVID-19 Quality Assessment Products

By Microbix Admin | October 20, 2020 Microbix Creates Further COVID-19 Quality Assessment Products

Ontario Helps Microbix Ensure Provincial COVID Testing Capacity

By Microbix Admin | October 13, 2020 Ontario Helps Microbix Ensure Provincial COVID Testing Capacity

Microbix Presenting COVID-19 Product Results To Industry

By Microbix Admin | September 22, 2020 Microbix Presenting COVID-19 Product Results To Industry

Microbix Announces Extension Of Warrant Expiry Dates

By Microbix Admin | September 17, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Announces Board Changes

By Microbix Admin | September 15, 2020 Microbix Announces Board Changes

Microbix’s REDx™ Controls Attain Australian TGA Registration

By Microbix Admin | September 10, 2020 Microbix’s REDx™ Controls Attain Australian TGA Registration

Q3 Fiscal 2020

By Microbix Admin | August 14, 2020

Curious To See How We Perform A COVID Test?

By Microbix Admin | July 21, 2020 Microbix

Microbix Shares Become Available For U.S. Investors

By Microbix Admin | July 14, 2020 Microbix Shares Become Available For U.S. Investors

Microbix COVID-19 QAPs Attain EU “CE Mark” Registration

By Microbix Admin | June 5, 2020 Microbix COVID-19 QAPs Attain EU “CE Mark” Registration

Microbix Announces Quality Products Distribution Agreement

By Microbix Admin | June 4, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Engaged To Develop & Supply Custom QAPs™

By Microbix Admin | June 2, 2020 Microbix Engaged To Develop & Supply Custom QAPs™

Microbix Expanding QAPs™ Production Capacity

By Microbix Admin | May 27, 2020 Microbix Expanding QAPs™ Production Capacity

Microbix Achieves Full Utilization Of Its Bioreactors

By Microbix Admin | May 19, 2020 Microbix Achieves Full Utilization Of Its Bioreactors

Microbix Announces Quality Products Distribution Agreement

By Microbix Admin | May 15, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Reports Record Second Quarter Sales

By Microbix Admin | May 14, 2020

Microbix Reports Results For Q2 Fiscal 2020

By Microbix Admin | May 14, 2020 Microbix Shares Become Available For U.S. Investors

Microbix Announces Quality Products Distribution Agreement

By Microbix Admin | May 12, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix COVID-19 QAPs Now Available for U.S. Labs

By Microbix Admin | May 7, 2020

Microbix Begins Providing COVID-19 Test Quality Products

By Microbix Admin | May 6, 2020 Microbix Begins Providing COVID-19 Test Quality Products

Microbix Announces Quality Products Distribution Agreement

By Microbix Admin | April 27, 2020 Microbix Announces Quality Products Distribution Agreement

Microbix Participating In COVID-19 Virtual Conference

By Microbix Admin | April 21, 2020 Microbix Participating In COVID-19 Virtual Conference

Microbix Attains Health Canada Establishment Licensing

By Microbix Admin | April 21, 2020 Microbix Attains Health Canada Establishment Licensing

How Microbix Core Competency Leads To COVID-19 Products

By Microbix Admin | April 14, 2020 Microbix

Understanding COVID-19 Mortality Rates

By Microbix Admin | April 13, 2020

Microbix & Oneworld Create COVID-19 Test Quality Program

By Microbix Admin | April 9, 2020 Microbix Attains Health Canada Establishment Licensing

Microbix Announces Annual And Special Meeting Voting Results

By Microbix Admin | April 1, 2020

Microbix Creates Quality Assessment Product For COVID-19 Tests

By Microbix Admin | March 30, 2020

Microbix Annual General Meeting Process Update

By Microbix Admin | March 25, 2020

Microbix Announces Quality Products Distribution Agreement

By Microbix Admin | March 24, 2020

Microbix Announces Issuance Of Stock Options

By Microbix Admin | February 25, 2020 Microbix Announces Addition to Board of Directors

Microbix Reports Results For Q1 Fiscal 2020

By Microbix Admin | February 13, 2020

Annual General Meeting (AGM) – March 31st, 2020 UPDATE!

By Microbix Admin | February 3, 2020

Microbix Completes Non-Brokered Private Placement Of $2.3 Million

By Microbix Admin | January 31, 2020

Microbix Reports Results For Fiscal 2019

By Microbix Admin | December 20, 2019 Microbix Shares Become Available For U.S. Investors

EUROGIN 2019

By Microbix Admin | December 4, 2019

Microbix Invited To Present Product Results At HPV Congress

By Microbix Admin | December 2, 2019

Microbix Wins Ontario Business Award

By Microbix Admin | November 18, 2019 Microbix Announces Addition to Board of Directors

Microbix Presenting Product Results At Industry Conference

By Microbix Admin | October 8, 2019

Microbix Presenting At StableView TECH19 Conference

By Microbix Admin | October 1, 2019 Microbix Announces Addition to Board of Directors

Microbix Presenting At Muskoka Capital Conference

By Microbix Admin | September 25, 2019

Microbix Quality Products Enter U.S. Market

By Microbix Admin | September 19, 2019 Microbix COVID-19 QAPs™ Now Available For U.S. Labs

Microbix Quality Products Attain European Registration

By Microbix Admin | September 5, 2019

Microbix Reports Results For Q3 Fiscal 2019

By Microbix Admin | August 12, 2019 Microbix Shares Become Available For U.S. Investors

Microbix Provides Bioreactor Update

By Microbix Admin | August 1, 2019

FedDev Ontario Supports New Microbix Facility In Mississauga

By Microbix Admin | July 30, 2019 Microbix Announces Quality Products Distribution Agreement

EMMD 11th Edition

By Microbix Admin | July 9, 2019

Microbix Reports Results For Q2 Fiscal 2019

By Microbix Admin | May 13, 2019

Microbix Will Be Exhibiting At The 35th Annual ASM Clinical Virology Symposium

By Microbix Admin | May 4, 2019

Microbix To Present At Bloom Burton Conference

By Microbix Admin | April 29, 2019 Microbix Shares Become Available For U.S. Investors

Microbix Announces Management Changes

By Microbix Admin | April 18, 2019 Microbix Announces Quality Products Distribution Agreement

Microbix Announces Annual Meeting Voting Results

By Microbix Admin | March 28, 2019

Microbix Will Be Exhibiting At The 29th Annual ECCMID

By Microbix Admin | March 18, 2019

Annual General Meeting (AGM) – March 27th, 2019

By Microbix Admin | March 5, 2019 Microbix Participating In COVID-19 Virtual Conference

Microbix Announces Issuance Of Stock Options

By Microbix Admin | February 25, 2019 Microbix Announces Addition to Board of Directors

Microbix Reports Results For Q1 Fiscal 2019

By Microbix Admin | February 12, 2019 Microbix Shares Become Available For U.S. Investors

Microbix Provides Quality Assessment Products Update

By Microbix Admin | February 5, 2019

Microbix Enhances Quality Management System

By Microbix Admin | December 24, 2018

Microbix Reports Results For Fiscal 2018

By Microbix Admin | December 21, 2018

Microbix Wins Business Award Of Excellence

By Microbix Admin | November 19, 2018

Microbix Exhibiting At MEDICA Trade Fair

By Microbix Admin | November 6, 2018

Microbix To Present At Muskoka Capital Conference

By Microbix Admin | September 27, 2018

Microbix Reports Record Third Quarter Sales

By Microbix Admin | August 14, 2018

Microbix Exhibiting At AACC Exposition

By Microbix Admin | July 26, 2018

Microbix To Present At Okanagan Capital Conference

By Microbix Admin | July 12, 2018 Microbix to Present at Bloom Burton Investor Conference